Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas

Analytical Cellular Pathology

Volumn 34, Issue 1-2, 2011, Pages 49-60

  Pelekanou, Vassiliki ^a,d   Notas, George ^a   Theodoropoulou, Katerina ^a   Kampa, Marilena ^a   Takos, Dimitrios ^a   Alexaki, Vassilia Ismini ^a   Radojicic, Jelena ^a   Sofras, Frank ^a   Tsapis, Andreas ^b,c   Stathopoulos, Efstathios N ^a   Castanas, Elias ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d JULES BORDET INSTITUTE   (Belgium)

Author keywords

Renal cell carcinoma conventional type; tumor necrosis factor receptor superfamily members (BCMA, TACI, TWEAK, Fn14); tumor necrosis factor superfamily members (BAFF, APRIL, TWEAK)

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; CYTOKINE RECEPTOR; FN14 PROTEIN; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR; TWEAK PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; B-CELL MATURATION ANTIGEN; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY NEOPLASMS; LIGANDS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13; TUMOR NECROSIS FACTORS;

EID: 79960799491     PISSN: 22107177     EISSN: 22107185     Source Type: Journal    
DOI: 10.3233/ACP-2011-0001     Document Type: Article

References (39)

1. V.I. Alexaki, G. Notas,V. Pelekanou, M. Kampa, M.Valkanou, P. Theodoropoulos, E.N. Stathopoulos, A. Tsapis and E. Castanas, Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development, J Immunol 183 (2009), 5948-5956.
2. L.C. Burkly, J.S. Michaelson, K. Hahm, A. Jakubowski and T.S. Zheng, TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease, Cytokine 40 (2007), 1-16. (Pubitemid 350088500)
3. M. Croft, The role of TNF superfamily members in T-cell function and diseases, Nat Rev Immunol 9 (2009), 271-285.
4. J. Diegmann, S. Tomiuk, J. Sanjmyatav, K. Junker, W. Hindermann and von F. Eggeling, Comparative transcriptional and functional profiling of clear cell and papillary renal cell carcinoma, Int J Mol Med 18 (2006), 395-403.
5. J. Duffield, The inflammatory macrophage: a story of Jekyll and Hyde, Clin Sci (Lond) 104 (2003), 27-38. (Pubitemid 36249921)
6. J.P. Dutcher, P. de Souza, D. McDermott, R.A. Figlin, A. Berkenblit, A. Thiele, M. Krygowski, A. Strahs, J. Feingold and G. Hudes, Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies, Med Oncol 26 (2009), 202-209.
7. B. Escudier, J. Bellmunt, S. Negrier, E. Bajetta, B. Melichar, S. Bracarda, A. Ravaud, S. Golding, S. Jethwa and V. Sneller, Phase III trial of bevacizumab plus interferon alfa-2 a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival, J Clin Oncol 28 (2010), 2144-2150.
8. S. Fuhrman, L. Lasky and C. Limas, Prognostic significance of morphologic parameters in renal cell carcinoma, Am J Surg Pathol 6 (1982), 655-663. (Pubitemid 13234762)
9. H.X. Gao, S.R. Campbell, L.C. Burkly, A. Jakubowski, I. Jarchum, B. Banas, M.A. Saleem, P.W. Mathieson, J.W. Berman, J.S. Michaelson and C. Putterman, TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells, Cytokine 46 (2009), 24-35.
10. M.L. Gumz, H. Zou, P.A. Kreinest, A.C. Childs, L.S. Belmonte, S.N. LeGrand, K.J. Wu, B.A. Luxon, M. Sinha, A.S. Parker, L.Z. Sun, D.A. Ahlquist, C.G. Wood and J.A. Copland, Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma, Clin Cancer Res 13 (2007), 4740-4749. (Pubitemid 47294780)
11. K. Gupta, J.D. Miller, J.Z. Li, M.W. Russell and C. Charbonneau, Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review, Cancer Treat Rev 34 (2008), 193-205.
12. M. Hahne, T. Kataoka, M. Schroter, K. Hofmann, M. Irmler, J.L. Bodmer, P. Schneider, T. Bornand, N. Holler, L.E. French, B. Sordat, D. Rimoldi and J. Tschopp, APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth, J Exp Med 188 (1998), 1185-1190. (Pubitemid 28443341)
13. M.L. Harrison, E. Obermueller, N.R. Maisey, S. Hoare, K. Edmonds, N.F. Li, D. Chao, K. Hall, C. Lee, E. Timotheadou, K. Charles, R. Ahern, D.M. King, T. Eisen, R. Corringham, M. DeWitte, F. Balkwill and M. Gore, Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose, J Clin Oncol 25 (2007), 4542-4549. (Pubitemid 350035310)
14. J. Harvey, G. Clark, C. Osborne and D. Allred, Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer, J Clin Oncol 17 (1999), 1474-1481. (Pubitemid 29220854)
15. J. Jones, H. Otu, D. Spentzos, S.Kolia, M. Inan,W.D. Beecken, C. Fellbaum, X. Gu, M. Joseph, A.J. Pantuck, D. Jonas and T.A. Libermann, Gene signatures of progression and metastasis in renal cell cancer, Clin Cancer Res 11 (2005), 5730-5739. (Pubitemid 41170297)
16. G. Kovacs, M. Akhtar, B.J. Beckwith, P. Bugert, C.S. Cooper, B. Delahunt, J.N. Eble, S. Fleming, B. Ljungberg, L.J. Medeiros, H. Moch, V.E. Reuter, E. Ritz, G. Roos, D. Schmidt, J.R. Srigley, S. Storkel, E. van den Berg and B. Zbar, The Heidelberg classification of renal cell tumours, J Pathol 183 (1997), 131-133.
17. M.E. Lenburg, L.S. Liou, N.P. Gerry, G.M. Frampton, H.T. Cohen and M.F. Christman, Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data, BMC Cancer 3 (2003), 31.
18. C.M. Lohse, M.L. Blute, H. Zincke, A.L. Weaver and J.C. Cheville, Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients, Am J Clin Pathol 118 (2002), 877-886. (Pubitemid 37047828)
19. F. Mackay, P.A. Silveira and R. Brink, B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling, Curr Opin Immunol 19 (2007), 327-336. (Pubitemid 46687013)
20. N. Maisey, Antitumor Necrosis Factor (TNF-a) Antibodies in the Treatment of Renal Cell Cancer, Cancer Invest (2007), 1-5.
21. P. Mhawech-Fauceglia, A. Allal, K. Odunsi, C. Andrews, F.R. Herrmann and B. Huard, Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas, Eur J Cancer 44 (2008), 2097-2100.
22. G. Mickisch, J. Carballido, S. Hellsten, H. Schulze and H. Mensink, Guidelines on renal cell cancer, Eur Urol 40 (2001), 252-255. (Pubitemid 34701894)
23. Y. Mizutani and O. Yoshida, Overcoming tumor necrosis factor-alpha resistance of human renal and ovarian carcinoma cells by combination treatment with buthionine sulfoximine and tumor necrosis factor-alpha. Role of tumor necrosis factoralpha mRNA down-regulation in tumor cell sensitization, Cancer 73 (1994), 730-737. (Pubitemid 24046621)
24. A. Molano, P. Lakhani, A. Aran, L.C. Burkly, J.S. Michaelson and C. Putterman,TWEAKstimulation of kidney resident cells in the pathogenesis of graft versus host induced lupus nephritis, Immunol Lett 125 (2009), 119-128.
25. J. Moreaux, J. Veyrune, J. De Vos and B. Klein, APRIL is overexpressed in cancer: link with tumor progression, BMC Cancer 9 (2009), 83.
26. R.J. Motzer and E. Basch, Targeted drugs for metastatic renal cell carcinoma, Lancet 370 (2007), 2071-2073. (Pubitemid 350296281)
27. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda, V. Grunwald, J.A. Thompson, R.A. Figlin, N. Hollaender, A. Kay and A. Ravaud, Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysisof prognostic factors, Cancer 116 (2010), 4256-4265.
28. R.J. Motzer, C.J. Nichols, K.A. Margolin, J. Bacik, P.G. Richardson, N.J. Vogelzang, D.F. Bajorin, P.N. Lara Jr., L. Einhorn, M. Mazumdar and G.J. Bosl, Phase III randomized trial of conventional-dose chemotherapy with or without highdose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors, J Clin Oncol, 25 (2007), 247-256. (Pubitemid 350003012)
29. M. Nakayama, N. Kayagaki, N. Yamaguchi, K. Okumura and H. Yagita, Involvement of TWEAK in interferon gammastimulated monocyte cytotoxicity, J Exp Med 192 (2000), 1373-1380.
30. B. Nardelli, O. Belvedere,V. Roschke, P.A. Moore, H.S. Olsen, T.S. Migone, S. Sosnovtseva, J.A. Carrell, P. Feng, J.G.Giri and D.M. Hilbert, Synthesis and release of B-lymphocyte stimulator from myeloid cells, Blood 97 (2001), 198-204. (Pubitemid 32061261)
31. H. Okano, K. Shiraki, Y. Yamanaka, H. Inoue, T. Kawakita, Y. Saitou, Y. Yamaguchi, N. Enokimura, K. Ito, N. Yamamoto, K. Sugimoto, K. Murata and T. Nakano, Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization, World J Gastroenterol 11 (2005), 4650-4654. (Pubitemid 41179517)
32. V. Pelekanou, M. Kampa, M. Kafousi, K. Darivianaki, E. Sanidas, D.D. Tsiftsis, E.N. Stathopoulos, A. Tsapis and E. Castanas, Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas, BMC Cancer 8 (2008), 76.
33. L. Planelles, J.P. Medema, M. Hahne and G. Hardenberg, The expanding role of APRIL in cancer and immunity, Curr Mol Med 8 (2008), 829-844.
34. S. Ramsey and M. Aitchison, Treatment for renal cancer: are we beyond the cytokine era? Nat Clin Pract Urol 3 (2006), 478-484. (Pubitemid 44377538)
35. E. Roosnek, M. Burjanadze, P.Y. Dietrich, T. Matthes, J. Passweg and B. Huard, Tumors that look for their springtime in APRIL, Crit Rev Oncol Hematol (2009), (in press).
36. C.N. Sternberg, I.D. Davis, J. Mardiak, C. Szczylik, E. Lee, J. Wagstaff, C.H. Barrios, P. Salman, O.A. Gladkov, A. Kavina, J.J. Zarba, M. Chen, L. McCann, L. Pandite, D.F. Roychowdhury and R.E. Hawkins, Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial, J Clin Oncol 28 (2010), 1061-1068.
37. M.L. Tan, J.P. Ooi, N. Ismail, A.I. Moad and T.S. Muhammad, Programmed cell death pathways and current antitumor targets, Pharm Res 26 (2009), 1547-1560.
38. F. Wang, L. Chen, Z.B. Mao, J.G. Shao, C. Tan and W.D. Huang, Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo, Oncol Rep 20 (2008), 135-139.
39. J.A. Winkles, The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting, Nat Rev Drug Discov 7 (2008), 411-425. (Pubitemid 351619113)